ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves New Task Orders For RMP Clinical Trials, Holds Up On Additional Grants

February 20, 1981

Intensity Modulated Therapy Safer Than Three-Dimensional Radiation

June 24, 2011

Local Labs Not As Accurate As Central Testing For HER2

August 30, 2002

New ACR Mammography Guidelines Suggest Annual Screening For Women Age 40-50

November 12, 1982

Reports On AACR Scientific Sessions

May 21, 1976

FDA Commissioner Holds Up IND While Reviewing Toxicology Guidelines

August 14, 1981